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BACKGROUND: On the basis of preclinical studies of NC-6004, a cisplatin-incorporated micellar formulation, we hypothesised that
NC-6004 could show lower toxicity than cisplatin and show greater anti-tumour activity in phase I study.
METHODS: A total of 17 patients were recruited in a range of advanced solid tumour types. NC-6004 was administered intravenously
(i.v.) every 3 weeks. The dose escalation started at 10mgm
 2 and was increased up to 120mgm
 2 according to the accelerated
titration method and modified Fibonacci method.
RESULTS: One dose-limiting toxicity (DLT) occurred in a patient who was given 90mgm
 2 of NC-6004, otherwise any significant
cisplatin-related toxicity was not observed or generally mild toxicity was observed. Despite the implementation of post-hydration and
pre-medication regimen, renal impairment and hypersensitivity reactions still developed at 120mgm
 2, which led to the conclusion
that the maximum tolerated dose was 120mgm
 2, and the recommended dose was 90mgm
 2, although DLT was not defined as
per protocol. Stable disease was observed in seven patients. The maximum concentration and area under the concentration–time
curve of ultrafilterable platinum at 120mgm
 2 NC-6004 were 34-fold smaller and 8.5-fold larger, respectively, than those for
cisplatin.
CONCLUSION: The delayed and sustained release of cisplatin after i.v. administration contributes to the low toxicity of NC-6004.
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Cisplatin, cis-diamminedichloroplatinum (II), is a platinum (Pt)-
based chemotherapy drug used to treat various types of cancers.
Clinical use of cisplatin is, however, associated with irreversible
renal toxicity, which necessitates the use of pre- and post-
hydration regimens, and excludes its use in patients with less
than normal renal function (Pinzani et al, 1994). Cisplatin therapy
also causes neurotoxicity, gastrointestinal toxicity (nausea and
vomiting), haematological toxicity, and irreversible ototoxicity
(Hartmann and Lipp, 2003). Furthermore, its anti-tumour efficacy
continues to be limited by either intrinsic or acquired resistance
(Kartalou and Essigmann, 2001). To overcome these cisplatin-
related disadvantages, various types of Pt analogues, including
carboplatin, oxaliplatin, satraplatin, and picoplatin have been
developed (Kelland and Sharp, 1999; Judson and Kelland, 2000;
Sharp et al, 2002). Another potential method for improving the
therapeutic indices of cisplatin is the incorporation of cisplatin
into polymeric micelles of varying size in the range of 20–100nm
composed of polyethylene glycol (PEG)-poly (amino acid) block
co-polymers, in which PEG constitutes the hydrophilic outer shell
of the micelle and cisplatin is incorporated into hydrophobic inner
core of the micelle (Yokoyama et al, 1996; Nishiyama et al, 1999,
2001b, 2003; Nishiyama and Kataoka, 2001a).
Preclinical studies carried out on NC-6004, cisplatin-incorpo-
rated polymeric micelles composed of PEG-poly (glutamic acid)
block co-polymers via polymer–metal complex formation (Figures
1 and 2), have indicated that it is preferentially distributed to
tumours by enhanced permeability and retention effect (Matsu-
mura and Maeda, 1986; Maeda and Matsumura, 1989; Maeda et al,
2000; Maeda, 2001), and demonstrates significantly lower toxicity
than cisplatin and greater anti-tumour activity (Uchino et al,
2005). On the basis of these results, a phase I clinical trial of
NC-6004 in patients with advanced solid tumours has been carried
out. The objectives of the study were to determine the maximum-
tolerated dose (MTD), the recommended dose (RD) for the phase
II, the dose-limiting toxicities (DLTs), the safety and tolerability
profile, and to explore evidence of anti-tumour activity, and the
pharmacokinetics of NC-6004.
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Ethics
The trial was an open-label, dose-escalating, phase I study
conducted at two sites in the United Kingdom; Newcastle General
Hospital and Belfast City Hospital. All procedures were reviewed
by Independent Ethics Committees, and were in accordance with
the protocol, the Helsinki Declaration (October 2000, and clarified
2002 and 2004), the Note for Guidance on Good Clinical Practice
(CPMP/ICH/135/95) approved in July 1996, and the applicable
regulatory requirements.
Administration of therapeutic agent
NC-6004 (NanoCarrier Co., Ltd Chiba, Japan) was a sterile solution
containing the equivalent of 2.5mgml
 1 cisplatin and could be
diluted in 5% dextrose before administration.
Dosing was performed by intravenous (i.v.) infusion of 500ml
over 60min, once every 3 weeks. Following the observation of
renal toxicities, hydration using 1000 to 1500ml of fluid,
immediately after NC-6004 infusion, was implemented for the rest
of the study. Later in the study, after the occurrence of four events
of hypersensitivity reactions, the following prophylactic treatment
was implemented at each cycle for all patients; 30min before
infusion – dexamethasone 20mg i.v., chlorphenamine 10mg i.v.,
and ranitidine 50mg i.v. Oral dexamethasone 4mg (twice a day),
ranitidine 150mg (twice a day), and chlorphenamine 4mg (three
times a day) could also be given if necessary on a per-patient
individualised basis for 48h after infusion.
Patients’ eligibility and dose escalation
Patients with histologically confirmed advanced solid tumours, for
which no standard therapy exists or has failed therapy, were
eligible for enrolment in this study, provided that the following
criteria were met: Eastern Cooperative Oncology Group performance
status of p2; age of X18 years; life expectancy of at least
12 weeks; a normal haematological profile, renal function, hepatic
function, and serum calcium level, no more than one previous
course of Pt therapy, with maximum cumulative doses of
480mgm
 2 of cisplatin, 1040mgm
 2 of oxaliplatin, or 42mgml
 1
min
 1 (min¼minutes) cumulative area under the concentration-
time curve (AUC) of carboplatin, and no chemotherapy, no
radiotherapy (except palliative radiation delivered to o20% of
bone marrow), no immunotherapy, or no corticosteroids (greater
than 10mg per day of prednisone or equivalent) within 4 weeks
before entering the study or patients who have not recovered from
adverse events because of agents administered more than 4 weeks
earlier. Patients who had severe hypersensitivity to Pt compounds,
ototoxicity assessed by audiometry (except senile hearing loss at
high frequency) or other neurotoxicity X grade 2 were ineligible
for enrolment in the study. Patients were excluded if they were
pregnant or lactating.
The dose of NC-6004 is, hereafter, always expressed as cisplatin
equivalent mgm
 2 of body surface area per injection. The starting
dose of NC-6004 was 10mgm
 2, one-tenth of the lethal dose in
10% in rat or one-third of the toxic dose low in dog. In stage 1,
(accelerated titration method), each dose was escalated at twice the
previous dose level until drug-related toxicity Xgrade 2 was seen
in cycle 1. Once the first drug-related toxicity Xgrade 2 in cycle 1
was seen, a minimum cohort of three patients was recruited, and
each dose was defined as 150% of the previous one in stage 2
(modified Fibonacci method) until MTD was reached. The dose
was modified according to the estimated creatinine clearance (Cl)/
GFR measured before each administration of NC-6004 as detailed
in Table 1. Intra-patient dose escalation was not permitted.
Toxicity was graded by the Common Terminology Criteria for
Adverse Events version 3.0. MTD was defined as the dose at which
one-third of patients experience DLT, and RD was the highest
dose, which gave rise to no more than one DLT out of a cohort of
six patients. DLTs were defined as grade 4 neutropenia associated
with fever (X38.51C) or diarrhoea X grade 2, grade 4 neutropenia
lasting X5 days without fever, grade 4 thrombocytopenia for X5
days, grade 3 or higher non-haematological toxicity (except liver
transaminase elevation, or nausea or vomiting treatable by anti-
emetic), and treatment delay 42 weeks before start of next cycle of
treatment because of unresolved toxicity.
Pretreatment assessment and follow-up studies
Assessment of medical history was completed during the 21 days
before the start of NC-6004 dosing. Safety was monitored
throughout the trial until the end of trial visit. In the treatment
phase, physical assessment, routine laboratory analysis, estimated
creatinine Cl, and concurrent illness/therapy were reviewed on
day 1 of cycle 1, then every week until week 7 and then every 3 weeks
thereafter, and at withdrawal from the trial. Adverse events were
reviewed during the first 4 days of cycle 1, then every week from
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Figure 1 Structure of cisplatin-PEG-poly(glutamic acid) block co-polymer
conjugate. PEG-pGlu, PEG-poly(glutamic acid); n, approximately 268;
m, approximately 40; x, approximately 24.
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Figure 2 Structure of cisplatin-incorporated polymeric micelle,
NC-6004. Core part, cisplatin residue bound to poly-L-glutamic acid.
Exterior part, PEG.
Table 1 Dose modification for changes in estimated creatinine clearance
or
51Cr-EDTA clearance
Estimated creatinine
clearance/GFR
NC-6004
dose
51Cr-EDTA
clearance
(in mlmin
 1)
NC-6004
dose
460mlmin
 1 100% of dose 460 100% of dose
50–60mlmin
 1 80% of dose 40–60 50% of dose
o50mlmin
 1 or
any drop from
51Cr-EDTA clearance
measurement
o40 Discontinue
baseline by 410%
calculated GFR
Abbreviations:
51Cr-EDTA clearance¼chromium-51-ethylenediaminetetraacetic
acid clearance; GFR¼glomerular filtration rate.
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withdrawal. The CT/MRI scans of all target and non-target lesions
were performed every 6 weeks and at withdrawal, and tumour
markers, if applicable, were assessed every 3 weeks. The Response
Evaluation Criteria in Solid Tumour (RECIST) was used to define
lesions and the criteria for objective tumour response. For pharmaco-
kinetic analysis, blood samples were taken at 0, 2, 4 and 8h after
administration on days 1, 2, 3, 4, 8, 15, and 22 and before cycle 2.
Pharmacokinetic analysis
Blood samples were centrifuged and separated plasma was
processed to produce three different forms of sample: total plasma,
gel filtrate and ultrafiltrate. Plasma (1ml) was stored for total-
plasma Pt analysis. Plasma (1ml) was centrifuged with a molecular
weight cutoff of 200000Da, and the eluant was analysed for
micellar Pt. Finally, a further 1ml of plasma was centrifuged with
a molecular weight cutoff of 30000Da to give an ultrafiltrate for
the determination of low-molecular weight Pt species, including
cisplatin. Concentration of total plasma Pt and micellar Pt (gel
filtrate) were measured using atomic absorption spectrometry
on Analyst 600 (Perkin-Elmer, Waltham, MA, USA) against
standards prepared in plasma. Ultrafiltrate samples were analysed
by inductively coupled plasma mass spectrometry on Element 2
(Thermo Scientific Inc., Waltham, MA, USA) against centrifuged
Pt standards at Durham University. Pharmacokinetic analysis was
performed using WinNonlin version 1.3 (Pharsight Corporation,
Mountain View, CA, USA) to calculate the maximum concentra-
tion (Cmax), the time to the maximum concentration (Tmax),
elimination half-life (t1/2), and the AUC from zero to infinity
(AUCinf) for all Pt species. Clearance (Cl) and volume of
distribution (Vz) were calculated for total plasma Pt.
RESULTS
Patient characteristics
The first patient was dosed on 15 May 2006 and the last study exit
visit occurred on 6 February 2008. In total, 17 patients were
enrolled and each received at least one dose of NC-6004,
representing the intention-to-treat population. Demographic
characteristics of patients are summarised in Table 2. All recruited
patients were Caucasian, with a median height of 170.0cm and a
median weight of 73.0kg. Cancer history of patients is summarised
in Table 3. The range of tumour types was large, with no specific
tumour type represented more across the different groups.
Tumour stage was similar between the dosing cohorts.
Dosing and toxicity
The process for dose escalation is shown in Table 3. In total, 41
doses were administered to 17 patients. The maximum number of
treatments was four cycles in three patients, and the mean number
of administrations per patient was 2.4 cycles. Dose escalation
started at 10mgm
 2 and was increased up to 40mgm
 2 following
the accelerated titration method. Owing to grade 2 renal toxicity in
cycle 1 of a patient at 40mgm
 2, reported as a serious adverse
event (SAE), the study entered stage 2 with a dose escalation up to
120mgm
 2 according to modified Fibonacci method.
Infusion-related adverse events are summarised in Table 4.
NC-6004 injection was well tolerated in terms of haematological
toxicities. Thus, one episode of grade 3 thrombocytopenia at
10mgm
 2 and grade 1 thrombocytopenia at 90mgm
 2 only were
observed (not DLTs). For non-haematological toxicity, the most
frequent related adverse events were fatigue (52.9%), anorexia and
nausea (47.1%), vomiting (41.2%), and hypersensitivity reaction
and renal impairment (35.3%). Significant cisplatin-related oto-
toxicity and neurotoxicity were not observed at any dose level.
One out of six patients at 90mgm
 2 experienced grade 3 fatigue in
cycle 1 (DLT). One out of three patients at 60mgm
 2 had grade 3
vomiting in cycle 1, and one patient in each 60, 90, and 120mgm
 2
developed grade 3 hypersensitivity reaction (not DLTs). The clinical
signs and symptoms of hypersensitivity reactions to NC-6004 were
urticarial rash, dizziness, sweating, cough, dyspnoea, hypotension,
tingling, swelling of tongue, lip, and pharynx, tightness in chest, and
burning sensation, some of which are typical reactions for Pt, and
they always developed after a minimum of two cycles of NC-6004.
Other infusion-related toxicities were grade 2 or lower. Despite the
implementation of post hydration (from 40mgm
 2 onwards) and
hypersensitivity prophylaxis (from 90mgm
 2 onwards), grade 2
renal toxicity accompanied by a reduction in dose and/or delay
in dose for 1 week was still observed at 90 and 120mgm
 2, and
grade 2 and 3 hypersensitivity reactions (SAEs) also developed
at 120mgm
 2. Following these events, it was considered that
adding further patients or increasing the dose level would not
be reasonable, and the study was discontinued at dosage level of
120mgm
 2. As the effect on renal function at 90mgm
 2 dosage
was less marked than that observed at 120mgm
 2, the 120mgm
 2
dosage was considered to be the MTD, and the RD of NC-6004
as monotherapy for further studies was therefore estimated to be
90mgm
 2, although renal toxicity and hypersensitivity reactions
were not defined as potential DLT per protocol.
Therapeutic response
Best overall response calculated by RECIST is shown in Table 3. No
patient was assessed as complete response or partial response.
Seven patients (41.2%) were evaluated as having had a stable
disease (SD) for longer than 4 weeks at the time of the study
completion, even though six of these had advanced Stage IV solid
tumours. It should be noted that only two out of eight patients
(25%) at the dose levels from 10 to 60mgm
 2 had a best response
of SD, however the SD ratios at 90 and 120mgm
 2 were 50 and
67% respectively, suggesting that the efficacy of NC-6004 is more
pronounced at higher dose levels. Overall, 14 patients (82.4%) died
or experienced tumour progression, and median progression-free
survival time was 49 days.
Table 2 Patient characteristics
NC-6004 dose level (in mgm
 2)
10 20 40 60 90 120 Total
n 1 1 3363 1 7
Age (years)
Range 55 63 45–65 45–56 48–80 40–71 40–80
Sex
M a l e 1 0 2241 1 0
F e m a l e 0 1 1122 7
ECOG PS
a
0 1 0 2142 1 0
1 0 0 1011 3
2 0 1 0110 3
Previous treatment
Chemotherapy 1 1 3352 1 5
Surgery 0 0 3333 1 2
Radiotherapy 0 1 1203 7
Other therapies for
cancer (targeted therapy,
immunotherapy, or
epigenetic therapy)
0 0 0212 5
Abbreviation: ECOG PS¼Eastern Cooperative Oncology Group performance
status.
aFor one patient at 60mgm
 2, ECOG PS was not assessed at screening,
but was assessed at day 1 before infusion.
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Dose
(mgm
 2)
Patient
no.
Primary
tumour (stage)
Cycles
received
No. of
DLT Events
Best overall
response
Stage 1
10 101 Lung (IV) 3 0 Hypersensitivity reaction at cycle 3 (previous cisplatin therapy) SD
20 102 Lung (IV) 2 0 PD
40 103 Colon (IV) 1 0 Grade 2 reduced renal function at cycle 1 (SAE). Cohort was
expanded with two more patients.
PD
204 Hepatic cell (IV) 4 0 SD
105 Colon (IV) 2 0 Grade 1 reduced renal function at cycle 1. Hydration was implemented
for the rest of study.
PD
Stage 2
60 106 Mesothelioma (IIIA) 2 0 Hypersensitivity reaction at cycle 2 (previous carboplatin therapy). PD
207 Colon (IV) 2 0 Hypersensitivity reaction at cycle 2 (previous oxaliplatin therapy). PD
108 Oesophagus (IV) 2 0 NE
90 209 Pancreas (IIA) 4 0 Hypersensitivity reaction at cycle 4 (Pt-naı ¨ve). Prophylactic treatment
was implemented for the rest of study.
SD
110 Oesophagus (IV) 2 0 Grade 2 reduced renal function at cycle 1. PD
112 GIST (IV) 2 0 Grade 2 reduced renal function at cycle 1. Cohort was expanded with
three more patients.
PD
113 Lung (IV) 2 0 SD
114 Pancreas (IV) 2 1 Grade 3 fatigue at cycle 1 (DLT). SD
215 Colon (IV) 2 0 PD
120 216 Melanoma (IV) 2 0 Grade 2 reduced renal function at cycle 1. PD
117 Melanoma (IV) 4 0 Grade 2 reduced renal function at cycle 1. Hypersensitivity reaction
at cycle 4 (SAE) (Pt-naı ¨ve).
SD
218 Renal cell (IV) 3 0 Hypersensitivity reaction at cycle 3 (SAE) (Pt-naı ¨ve). SD
Abbreviations: DLT¼dose-limiting toxicity; GIST¼gastrointestinal stromal tumour; PD¼progressive disease; Pt¼platinum; NE¼not estimated; SAE¼serious adverse event;
SD¼stable disease.
Table 4 Summary of all related adverse events
NC-6004 dose level (in mgm
 2)
10 20 40 60 90 120 Total
n 11336 3 1 7
Haematological toxicity
Blood and lymphatic system disorders
Thrombocytopenia 1 0001 0 2
Non-haematological toxicity
Gastrointestinal disorder
Constipation 0 0000 1 1
Dry mouth 0 0010 0 1
Nausea 0 1114 1 8
Paraesthesia oral 0 0000 1 1
Tongue ulceration 0 0001 0 1
Vomiting 0 0114 1 7
General disorder and administration site conditions
Fatigue 1 1014 2 9
Infusion site reaction 0 1000 0 1
Malaise 0 0000 1 1
Immune system disorders
Hypersensitivity 1 0021 2 6
Metabolism and nutrition disorders
Anorexia 0 0214 1 8
Decreased appetite 0 0010 0 1
Dehydration 0 0001 0 1
Hypomagnesemia 0 0001 0 1
Nervous system disorder
Dizziness 0 0000 1 1
Neuropathy peripheral 1 0010 0 2
Peripheral sensory neuropathy 0 0001 0 1
Renal and urinary disorder
Renal impairment 0 0202 2 6
Skin and subcutaneous tissue disorder
Alopecia 0 0000 1 1
Rash 0 0000 1 1
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Pharmacokinetic parameters for Pt measured per cohort in the
three different matrices are shown in Table 5. A typical plasma
concentration–time profile is also shown in Figure 3.
Pharmacokinetics of total plasma Pt was characterised by longer
t1/2, and higher Cmax and AUCinf with smaller Vz and Cl compared
with those of cisplatin, indicating that the blood circulation of
cisplatin was prolonged by the incorporation into the micelles.
Thus, the Cmax and AUCinf of NC-6004 at 120mgm
 2 were approxi-
mately 11-fold higher than those of cisplatin at an equivalent dose
(Kitajima et al, 1987). The t1/2 of NC-6004 at 120mgm
 2 was longer
than that of cisplatin at an equivalent dose, 14.6min for the initial
phase and 73.8h for the terminal phase (Kitajima et al, 1987).
The Vz and Cl of NC-6004 were smaller than those of cisplatin,
52l and 350mlh
 1, respectively (Calvert et al, 1993). The AUCinf
and Cmax of NC-6004 increased in a dose-dependent manner, and
there was no apparent change in Cl with increasing dose.
For the gel-filterable Pt (intact micellar formulation), the Tmax
was similar to that of total plasma Pt, the t1/2 generally mirrored
that of total plasma Pt, and the Cmax and AUCinf values were
approximately 88% of those of total plasma Pt.
For the ultrafilterable Pt (active species including cisplatin), the
Cmax at120mgm
 2 was 34-fold lower than that of non-protein-bound
cisplatin after the administration of an equivalent dose of cisplatin
(Kitajima et al, 1987), which might be responsible for the lower
incidence of toxicity compared with that associated with cisplatin
therapy. Conversely, t1/2 and AUCinf at 120mgm
 2 of NC-6004 were
230-fold and 8.5-fold larger, respectively, than those of non-protein-
bound cisplatin after the administration of an equivalent dose of
cisplatin (Kitajima et al, 1987). The persistence of active Pt species might
indicate an improved efficacy of NC-6004. Furthermore, Tmax (24h or
greater) was delayed compared with that of total plasma Pt or gel-
filterable Pt, suggesting that NC-6004 provides a delayed and sustained
release of potentially active Pt species after the administration period.
DISCUSSION
NC-6004 was well tolerated with minimal nephrotoxicity and no
significant myelosuppression, ototoxicity, emesis, or neurotoxicity,
but a higher rate of hypersensitivity reactions than predicted. No
DLT per protocol was seen at doses up to 90mgm
 2 where 1 DLT
(grade 3 fatigue) was experienced by one out of six patients, and
no further DLT per protocol was seen at 120mgm
 2 when the
study was discontinued. In general, the toxicities of NC-6004 were
less severe and less frequent compared with cisplatin, particularly
nausea/vomiting, anorexia, alopecia, and haematological toxicity.
In this study, dose delays/reductions were mainly due to effects
on renal function. Despite the introduction of 1 to 1.5l of fluid
over 2h, following NC-6004 administration, rising creatinine and/
or reduction in estimated creatinine Cl or
51Cr-EDTA Cl affected
two out of six patients at 90mgm
 2 and two out of three patients
at 120mgm
 2, although the creatinine level returned to baseline in
2 weeks. Cisplatin therapy requires a total 8h hydration,
comprising 1–2l over 4h of hydration, both before and after the
administration of cisplatin, to prevent nephrotoxicity. Another
potential advantage of NC-6004 over cisplatin is, therefore, the
reduced need for hydration, and that renal impairment was kept to
minimum by modest hydration. Whether hydration is absolutely
necessary for NC-6004 therapy to reduce the incidence of renal
impairment remains to be assessed in a future trial.
Dose interruptions due to toxicity in this study were all related
to hypersensitivity reactions, which occurred unpredictably at four
Table 5 Pharmacokinetic parameters per cohort for total, micellar, and ultrafiltrable Pt of NC-6004 (mean±s.d.)
Analyte Dose (mgm
 2) Tmax (h) Cmax (lgml
 1) t1/2 (h) AUCinf (hlgml
 1) Vz (l) Cl (mlh
 1)
Total Pt 10 4.0 5.70 24 234 3.0 85
20 5.4 12.20 20 492 2.0 68
40 2.0±0.1 25.9±2.4 62±18 1135±78 5.5±2.0 62±11
60 2.7±1.2 29.9±13.8 93±41 1354±638 6.7±0.5 107±69
90 5.2±2.2 60.8±12.5 129±40 2836±554 11.8±6.9 61±20
120 4.4±2.5 85.4±10.8 158±48 4377±563 10.9±3.8 48±9
Micellar Pt 10 —
a —
a —
a —
a
20 6.4 8.90 16 237
40 2.0±0.1 13.9±10.4 67±56 509±204
60 5.0±1.7 14.4±7.3 18±7 385±153
90 4.8±2.4 42.4±20.3 39±27 1579±939
120 3.1±1.5 84.6±8.1 87±37 3857±1171
UF Pt 10 48.7 0.009 114 1.7
20 23.5 0.022 71 2.5
40 24.0±0.1 0.045±0.014 141±126 4.7±2.1
60 26.5±20.9 0.096±0.022 114±47 13.2±5.8
90
b 20.5±7.6 0.205±0.114 123±44 22.6±10.0
120
c 26.4 0.131 115 22.9
Abbreviations: AUCinf¼area under concentration–time curve from zero to infinity; Cmax¼maximum concentration; Cl¼clearance; Pt¼platinum; QC¼quality control;
Tmax¼time to maximum concentration; UF Pt¼ultrafilterable platinum; Vz¼volume of distribution.
aData not valid – QCs out with acceptance limit.
b1 data was not valid –
QCs out with acceptance limit.
c2 data were not valid – QCs out with acceptance limit.
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Figure 3 Plasma Pt concentration–time curve from a patient
treated at 90mgm
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 2) in six patients.
The first three patients had previous Pt therapy and the last three
patients were Pt-naı ¨ve, thus, the occurrence of hypersensitivity
reaction depends on neither dose level nor the previous Pt
exposure. The use of a prophylactic regimen of dexamethasone,
ranitidine, and chlorphenamine, previously described, was not
sufficient to prevent hypersensitivity reactions in two patients at
120mgm
 2, therefore a more stringent prophylactic regimen
(Kwon et al, 2002) might be necessary. As most of the patients
recruited in this Phase I study progressed by the end of cycle 2, and
hypersensitivity reactions developed after a minimum of two cycles
of NC-6004, despite the pre-medication, it was considered that this
phase I study was not the appropriate setting to assess alternative
pre-medication strategies. Therefore, the study was discontinued, so
that this problem could be assessed in a future trial. In preclinical
studies, the antigenicity of NC-6004 was examined compared with
cisplatin, polymer vehicle, polymer-bound cisplatin (not in a micelle
form), and cisplatin–plasma protein complex. The results indicated
that cisplatin and polymer vehicle are not antigenic, and the highest
extent of antigenicity observed was in cisplatin–plasma protein
complex, followed by NC-6004 and then polymer-bound cisplatin
(not in a micelle form). This suggests that the hypersensitivity
reaction to NC-6004 may have been due to plasma protein-bound
cisplatin, which is formed by rapid binding of plasma protein to
released cisplatin, which then circulates in the blood for a prolonged
period. However, the mechanism has not yet been fully clarified.
Taking account of the incidence of hypersensitivity reaction
and renal impairment, 120mgm
 2 was considered to be close to
the MTD, such that 90mgm
 2 was most likely the RD for
monotherapy for future studies, although the definition per
protocol of the MTD was not actually reached.
In spite of the patients generally being heavily pretreated, some
evidence of disease stabilisation was seen, and seven patients
demonstrated SD after 6 weeks of treatment. Efficacy will be
further assessed in a future trial.
The pharmacokinetic analysis indicated the prolonged circula-
tion of NC-6004 in the blood, and delayed and sustained release of
potentially active Pt species after the administration of NC-6004.
More importantly, the observed lower Cmax for ultrafilterable Pt
compared with that of non-protein-bound cisplatin, after the
cisplatin injection, might result in the reduction of cisplatin-
related toxicity. Furthermore, the higher AUCinf and t1/2 for ultra-
filterable Pt compared with that of non-protein-bound cisplatin
after the cisplatin injection might enhance the efficacy of NC-6004.
However, an increase in the AUC of plasma protein-bound cisplatin
because of rapid binding of plasma protein to released cisplatin might
result in a higher risk of hypersensitivity reaction.
In conclusion, this Phase I study has confirmed that NC-6004
exhibits pharmacokinetic characteristics completely different from
those of cisplatin, resulting in the reduction of cisplatin-related toxicity
and the improvement of patient’s quality of life so that the patients can
take therapy without hospitalisation for hydration and treatment of
cisplatin-related toxicities. The data obtained from this study are
believed to open new avenues for the use of this micellar formulation
i nt h ec l i n i c .T h ea s s e s s m e n to ft h em o s ta p p r o p r i a t ep r o p h y l a c t i c
regimen for hypersensitivity reactions, whether hydration is necessary
and of efficacy are now underway in ongoing NC-6004 studies.
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